Valuation: Cybin Inc.

Market Cap 613M 436M 381M 353M 324M 42.05B 623M 4.21B 1.65B 20.53B 1.64B 1.6B 70.89B P/E 2027 *
-2.45x
P/E 2028 * -2.96x
Enterprise Value 126M 89.72M 78.42M 72.52M 66.55M 8.64B 128M 865M 340M 4.22B 337M 330M 14.57B EV / Sales 2027 *
-
EV / Sales 2028 * 2.9x
Free-Float
97.25%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Cybin Inc.

1 day-0.36%
1 week-0.36%
Current month+3.56%
1 month+49.45%
3 months+24.45%
6 months-10.87%
Current year-16.32%
1 week 6.4
Extreme 6.4
7.48
1 month 4.45
Extreme 4.45
7.48
Current year 3.76
Extreme 3.76
8.97
1 year 3.76
Extreme 3.76
9.12
3 years 3.76
Extreme 3.76
28.04
5 years 3.76
Extreme 3.76
128.44
10 years 3.76
Extreme 3.76
128.44
Manager TitleAgeSince
Chief Operating Officer 37 2016-10-12
Chief Executive Officer 51 2026-04-19
Director of Finance/CFO 56 2020-11-04
Director TitleAgeSince
Chairman 51 2020-11-04
Director/Board Member 37 2016-10-12
Director/Board Member 65 2020-11-04
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Tax

Chief Executive Officer

-791,421 1.5817%
5/27/26 Tax

Investor Relations Manager

-80,395 0.1607%
5/27/26 Tax

Founder

-791,421 1.5817%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-0.36%-19.09%-58.59% 436M
-3.42%+4.90%+61.15%+87.70% 55.98B
-0.43%-2.17%+52.24%+70.75% 53.69B
+1.29%-5.77%+4.57%+426.26% 23.29B
-0.40%-0.42%-17.95%-15.02% 23.15B
-5.95%-2.58%+30.67%-9.47% 20.58B
-1.49%-0.05%+31.47%-30.47% 17.76B
-4.55%-1.95%+192.65%+349.58% 16.09B
-6.91%-5.83%+26.53%+644.30% 15.93B
+0.01%-1.56%+23.96%+189.84% 14B
Average -2.19%+0.23%+38.62%+165.49% 24.09B
Weighted average by Cap. -2.15%-0.87%+45.49%+149.73%

Financials

2027 *2028 *
Net sales - 3.53M 2.51M 2.2M 2.03M 1.86M 242M 3.59M 24.22M 9.52M 118M 9.44M 9.23M 408M
Net income -260M -185M -162M -150M -137M -17.84B -264M -1.78B -701M -8.71B -695M -680M -30.08B -266M -189M -166M -153M -141M -18.26B -271M -1.83B -717M -8.91B -711M -696M -30.78B
Net Debt -487M -347M -303M -280M -257M -33.4B -495M -3.34B -1.31B -16.31B -1.3B -1.27B -56.32B -602M -429M -375M -347M -318M -41.35B -613M -4.14B -1.63B -20.19B -1.61B -1.58B -69.71B
Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
100
Date Price Change Volume
26-07-17 $7.198 +2.24% 440,452
26-07-16 $7.040 +8.14% 3,780,989
26-07-15 $6.510 -2.54% 766,161
26-07-14 $6.680 -0.30% 709,193
26-07-13 $6.700 -2.47% 2,073,059
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.884CAD
Average target price
53.29CAD
Spread / Average Target
+439.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HELP Stock